WALTHAM, Mass.--(BUSINESS WIRE)--June 28, 2006--Interleukin Genetics (AMEX: ILI - News) today announced the completion of the expansion and upgrade of its Laboratory Operations. This will allow the company to meet the demand for its DNA risk assessment tests. Interleukin has added equipment and staff to enable the company to improve turnaround time for test results and to increase efficiencies and overall capacity for future growth.
